Fundación Respirar

Buenos Aires, Buenos Aires C1426ABP

1 studies enrolling now · 2 studies all time

What they study most

Atopic Dermatitis, Cardiovascular Diseases, Eczema, Obesity

Studies at this site

• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis — Enrolling by invitation
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — Completed